HUGEL announced on the 22nd that it received product approval for the botulinum toxin 'Botulax' from the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) on the 20th (local time).
The approved products are Botulax 50IU, 100IU, and 200IU. It has obtained usage approval for a total of five indications for aesthetic and therapeutic purposes, including eyelid spasms, periorbital wrinkles, glabellar lines, upper limb spasticity after stroke, and pediatric cerebral palsy associated clubfoot.
HUGEL plans to officially launch Botulax in the United Arab Emirates at the end of April. The distribution and sales in the local beauty sector will be handled by Medica Group, its partner in the Middle East and North Africa (MENA). Medica Group is headquartered in the UAE and operates branches in Saudi Arabia, Lebanon, and elsewhere, securing a strong distribution network in the region.
HUGEL stated that it will implement a reasonable pricing policy and differentiated marketing strategies in collaboration with Medica Group to rapidly expand its market share. In particular, it plans to maximize synergy with the HA filler 'Revolax' (domestically known as The Chaeum), which is approved and sold in the UAE since 2023, promoting an integrated portfolio.
Currently, HUGEL is in the process of obtaining approval for botulinum toxin in key countries such as Saudi Arabia and Qatar. The company noted, 'The MENA region is the fastest-growing area in the global medical aesthetic market, and this product approval is expected to drive growth in the MENA region.' It also stated, 'We will expand our business base through excellent product quality and active partnerships with Medica Group.'